Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. by Bähler, C. et al.
Bähler et al. BMC Gastroenterology  (2017) 17:138 
DOI 10.1186/s12876-017-0681-yRESEARCH ARTICLE Open AccessTrends in prevalence, mortality, health care
utilization and health care costs of Swiss
IBD patients: a claims data based study of
the years 2010, 2012 and 2014
Caroline Bähler1* , Stephan R. Vavricka2, Alain M. Schoepfer3, Beat Brüngger1 and Oliver Reich1Abstract
Background: Real-life data on inflammatory bowel disease (IBD) prevalence and costs are scarce. The aims of this
study were to provide an overview of the prevalence, mortality, health care utilization and costs of IBD patients in
Switzerland in the years 2010, 2012, and 2014.
Methods: Based on claims data of the Helsana-Group, prevalence of IBD was assessed for 2010, 2012 and 2014.
Mortality rates, costs (inpatient, outpatient, medication costs) and utilization (visits, hospitalizations) were compared
between patients with and without IBD, and between IBD patients treated with and without biologics. Results were
extrapolated to the Swiss general population using national census data. Multivariate linear regression was used to
identify socio-demographic and regional factors influencing total costs.
Results: The overall extrapolated prevalence rates of IBD were 0.32% in 2010, 0.38% in 2012, and 0.41% in 2014.
Mortality rate didn’t differ between the IBD and non-IBD population. Costs increased annually by 6% in IBD versus
2.4% in non-IBD subjects, which was solely due to increased outpatient costs. Almost one-fourth of IBD patients
were hospitalized at least once a year. Costs were higher in IBD patients treated with biologics (OR = 3.98, CI: 3.72-4.
27, p < 0.001) when compared to IBD patients without biologic therapies. Over 70% of the total costs in IBD patients
treated with biologics were due to drug costs, compared with 28% in patients without use of biologic therapies, whereas
inpatient costs didn’t differ.
Conclusions: The prevalence of IBD seems to be increasing in Switzerland. Outpatient costs increased substantially, while
no decrease in inpatient costs was found. Treatment of IBD is more and more based on biologic therapies.
Keywords: Inflammatory bowel disease, Prevalence, Mortality, Health care costsBackground
Inflammatory Bowel Diseases (IBD) are chronic disabling
gastrointestinal disorders characterized by a chronic inflam-
mation that can affect the gastrointestinal tract. Ulcerative
colitis (UC) and Crohn’s disease (CD) represent the two
main forms of IBD, but their etiology and pathophysiology
are not yet entirely understood. Genetic susceptibility along
with immunological and environmental factors seems to be
responsible for the onset of IBD [1–3]. Prevalence estimates* Correspondence: caroline.baehler-baumgartner@helsana.ch
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in Western countries [4–6]. Prevalence and incidence of
IBD were shown to have increased over the last years in
many, predominantly industrialized, countries [7–10].
IBD may be associated with further physical and
mental disorders like iron deficiency or depression
compared with the general population [11–14]. These
findings result in increased resource utilization in
terms of treatment costs, hospitalizations and need
for surgeries [15–18]. Moreover, IBD may generate
high health care costs as patients are in need of sev-
eral different medications. The treatment of possible
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tween European countries when assessing health care
costs [19]. As claimed by the authors, these differences
didn’t result from variations in local pricing, but were ra-
ther due to the divergent management of IBD in terms of
medical treatment and hospitalization [19].
International guidelines base their recommendations
for the treatment of CD [20] and UC [21, 22] on activity
and location of the disease. The management plan is also
influenced by the disease pattern (relapse frequency,
response to previous medications or possible side-
effects) and should therefore be individualized [20, 21].
This individualized treatment approach may lead to
differences in the practice between clinicians, [21] which
may also be true for the management of CD [23, 24].
In Switzerland, only limited data on the prevalence
and mortality of IBD is available. Furthermore, no infor-
mation on the diagnosis (e.g. ICD codes) is available in
the ambulatory setting. Data concerning health care
costs and utilization in IBD patients who are treated by
office-based gastroenterologists and general physicians
are scarce. The Swiss IBD Cohort, founded in 2004,
mainly consists of patients recruited from (university)
hospital divisions and patients treated in the hospital
outpatient setting [25, 26]. In addition, many former
studies on the economic burden of IBD can be consid-
ered outdated due to the introduction of new and effect-
ive, but expensive medical therapies.
Switzerland has a mandatory national health insurance
system with a cost sharing compulsory basic coverage for
each resident consisting of co-payments and deductibles.
The height of the deductible is to some extent elective,
whereby higher deductibles lead to lower premiums. In
contrast, it may increase the amount of out-of-pocket ex-
penses. Managed care models also go along with lower
premiums, but they in turn restrain the free choice of phy-
sicians. In absence of population-based data on IBD,
health care claims data, like the database of the Helsana-
Group, are a useful approach to display the prevalence,
the health care costs and health care utilization of IBD.
Claims data are reliable, practice-based and provide a high
level of completeness, independent of the insurance cover-
age. As the Helsana-Group covers a relatively large and
geographically diverse part of the Swiss population, the
extrapolated findings can be regarded as representative for
Switzerland.
Aim of the study
The aim of the present study was to provide a compre-
hensive and updated overview of the prevalence, mortal-
ity as well as the health care utilization and costs in IBD
patients in Switzerland. In order to assess the time
trends, we analyzed the years 2010, 2012, and 2014. Fur-
thermore, we sought to evaluate the proportion of IBDpatients treated with biologics, as well as their impact on
health care costs and utilization. The comparison of
patients treated with and without biologic therapies will
provide important additional insights of the real world
setting of IBD.
We assume that prevalence and costs of IBD are rising
over the observed time period. We hypothesize that out-
patient costs are higher in IBD patients with biologic
prescriptions compared to those without, while in turn
inpatient costs are lower.Methods
Study design
This is a retrospective cohort study of enrollees with
and without IBD, who were insured at Helsana-Group in
the period between 2010 and 2014. Subjects who died
within this period were also included, except in the cal-
culation of the health care costs and the health care
utilization. In order to avoid biases due to the cohort
effect, we compared three observation periods (using the
following three data points: 2010, 2012 and 2014), rather
than to follow one cohort for 5 years. Therefore, each of
the three study periods had a unique base population,
whereby some patients might be included in both or in
all three of those periods.
According to the Swiss Federal Law on data protection,
this study was exempted from ethics committee approval
as all data were anonymized, retrospective, pre-existing,
and de-identified in order to protect the privacy of pa-
tients, physicians, and hospitals. The study protocol was
approved by the Helsana-Group.Study population
The Helsana database underlying this study included
mandatory health insurance claims from approximately
1.2 million persons per year, covering about 15% of the
whole Swiss population. Insured persons were eligible
for inclusion if they were obligatory insured by Helsana
in the given year (2010, 2012, and 2014, respectively),
and if they were at least 1 year old. A total of 1,209,638
individuals in 2010, of 1,206,466 in 2012, and of
1,196,505 persons in 2014 were identified in the Helsana
database. In sum 126,972 (3.5%) individuals had to be
excluded because they were younger than 12 months of
age (1.0%) or due to missing data (2.5%), e.g. individuals
living abroad, or nursing home residents whose medical
costs were covered by a fixed rate, the reason why no
detailed information on the type of medication was
available. To calculate health care costs and health care
utilization, all decedents (n = 34,545) as well as individuals
who dropped out of the Helsana-Group (n = 46,487) dur-
ing a given year were excluded in order to have the full
range of data for the given year.
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In absence of epidemiological data including medical
diagnoses (e.g. International Classification of Diseases
System, ICD), the WHO Anatomical therapeutic chem-
ical (ATC) classification system was used to identify
patients with chronic conditions [27]. All prescription
drug items are coded and assigned to an ATC code in
the Helsana database. Using the pharmacy-based cost
group (PCG) model, certain ATC codes can be assigned
to different chronic diseases. This mapping approach is
frequently used as a reliable method to identify chronic-
ally ill patients in administrative data samples if diagno-
sis information is unavailable [28–30]. We used a
modified version of the PCG-Model [31] including 21
chronic conditions in our analysis: acid-related disor-
ders, bone diseases (osteoporosis), cancer, cardiovascular
diseases (incl. Hypertension), dementia, diabetes melli-
tus, epilepsy, glaucoma, gout/hyperuricemia, HIV, hy-
perlipidemia, iron deficiency anemia, migraine, pain,
Parkinson’s disease, psychological disorders (sleep disor-
ders, depression), psychoses, respiratory illness (asthma,
COPD), rheumatologic conditions, thyroid disorders,
and tuberculosis.
Patients were classified via ATC codes as IBD if they
were prescribed 5-aminosalicylic acid (5-ASA: mesala-
zine and sulfasalazine, prescribed by any physician)
and/or if they had at least one anti-inflammatory drug
prescription (immunosuppressants, TNF antagonists/bi-
ologics, and/or integrin inhibitors) in combination with
at least one visit to a gastroenterologist within 1 year.
Immunosuppressants included methotrexate, azathio-
prine, and mercaptopurine, biologics comprised inflixi-
mab, adalimumab, golimumab, and certolizumab pegol.
The prescription of integrin inhibitors (Vedolizumab)
has also been considered for inclusion, although Vedoli-
zumab got its first marketing approval in Switzerland in
January 2015. In line with this, we did not find any
medical claim for Vedolizumab in any of the observed
years. Since 2012, Switzerland has introduced a DRG
(“diagnosis related group”) system. The DRG system
provides a more detailed analysis of hospitalized IBD
patients, which allowed for the calculation of the sensi-
tivity and specificity of the IBD definition used in our
study. According to preliminary analysis, the most fre-
quently prescribed medications during the course of 1
year in our hospitalized patients with UC or CD were
corticosteroids. However, the inclusion of corticoste-
roids in the definition would have resulted in a lower
specificity.
Further population characteristics were used as covari-
ates. They included sex, age group (1-17, 18-40, 41-60,
61+), language area, type of insurance coverage (man-
aged care model, accident coverage, and deductible
class), canton of residence, type of residence, as well ashaving supplementary insurance and purchasing power
of the corresponding zip code as proxies for socioeco-
nomic status.
Health care costs
We aimed to determine the economic burden of IBD
from a social insurance payer perspective including all
parts of direct health care costs. Annual total health care
costs in IBD patients were obtained from providers’
claims and defined as the total amount of outpatient and
inpatient costs per patient per year with mandatory in-
surance coverage. Inpatient costs contained payments
for hospital treatments (over-night stays <24 h), hospi-
talizations (over-night hospital stays equal to or longer
than 24 h), rehabilitation, nursing home, transitional
care services and emergency transport services. Costs
were not limited to an IBD indication in IBD patients.
Costs from the outpatient setting comprised payments
for office-based physician visits (primary care physician
and specialists), hospital outpatient visits, paramedical
visits (e.g. physiotherapists), home care nursing services,
medications, laboratory tests and medical devices. Medi-
cation costs are presented separately in the Tables. All
costs are quoted in Swiss Francs (1 CHF = 1.017 US$;
effective August 2016).
The amount of out-of-pocket payments could not be
considered in this study because they are not reimbursed
by the health insurer. However, these are estimated to be
a very small proportion of 1.5% of total payments.
Health care utilization
Health care utilization is composed of outpatient visits,
hospitalizations and of the use of IBD specific medica-
tions. Hospitalizations and outpatient visits were both
not limited to an IBD indication in IBD patients. In the
outpatient setting, visits were defined as direct contacts
between patient and physician. The following supple-
mentary measures are provided of outpatient visits in
2014, each per patient/year in those with at least one
visit in the given year: the total number of outpatient
visits, the number of primary care physician visits
(primary care physicians, general internists), the num-
ber of specialist visits, and of hospital outpatient
visits, as well as the number of different physicians
contacted. Hospitalizations were defined as inpatient
stays for 24 h or longer. Furthermore, the average
length of hospital stay was assessed in those patients
with at least one hospitalization.
Statistical analysis
Using our IBD classification, we calculated the preva-
lence rates of IBD stratified by age and sex for the years
2010, 2012 and 2014 by dividing the number of patients
with IBD by all insured persons of the corresponding
Table 1 Prevalence estimates of IBD extrapolated to the
general Swiss population for the years 2010, 2012, and 2014
2010 2012 2014
Prevalence /100,000 (CI)
Total 318 (308-329) 376 (365-388) 408 (396-420)
Men (all ages) 284 (270-298) 338 (322-353) 372 (356-388)
1-17 24 (13-34) 25 (14-37) 19 (10-29)
18-40 213 (191-236) 255 (230-281) 303 (276-330)
41-60 373 (343-403) 447 (412-481) 469 (435-504)
60+ 495 (458-532) 567 (527-606) 627 (585-669)
Women (all ages) 352 (337-367) 414 (397-430) 443 (426-460)
1-17 20 (11-30) 27 (16-38) 26 (16-37)
18-40 299 (273-326) 321 (293-349) 381 (350-412)
41-60 445 (413-478) 552 (514-590) 564 (526-602)
60+ 535 (502-568) 616 (580-653) 648 (611-685)
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to show differences between the characteristics of indi-
viduals with and without (control group) IBD using fish-
er’s exact test for dichotomous variables, Wilcoxon rank
sum test for continuous, and chi-squared test for
categorical variables. Due to the heterogeneity of the
Helsana population, it is possible to extrapolate the pro-
portion of patients with IBD for each year to the whole
Swiss population by using census data from the Swiss
Federal Office of Statistics. The stratification for the
extrapolation was carried out by age group, sex and 26
cantons of residence using the R package ‘survey’ [32].
We further calculated the annual all-cause mortality in
patients with IBD for the three study periods. Direct
health care costs and health care utilization are pre-
sented separately for patients with and without IBD.
Mortality rates, total health care costs and health care
utilization were also extrapolated to the Swiss general
population.
Multivariate logistic (prevalence and mortality) or lin-
ear (health care costs and utilization) regression model-
ing, including year, sex, age group and canton of
residence as independent factors, was conducted for the
description of time trends. Additional, linear multivariate
regression modeling was performed to predict the total
costs in IBD patients, adjusting for the following influen-
cing factors: age group, sex, treated comorbid condi-
tions, regional variables, health insurance plan, as well as
socioeconomic status. In the presence of a skewed distri-
bution of costs, log transformation was used. Finally, dif-
ferences within IBD patients with and without the use of
biologics were analyzed regarding health care utilization
and costs, thereby again adjusting for the above influen-
cing factors. Analyses were conducted using R statistics,
version 3.2.0 [33].
Results
The number of persons included in the final study
sample comprised 1,170,913 in 2010, 1,163,351 in
2012, and 1,151,373 in 2014. Overall, 51.7% of the in-
dividuals were women. The median (IQR) age was
43.0 (35) in men and 46.0 (38) in women. The age
distribution of men and women in the three study
populations is shown in Additional file 1: Table S1.
Prevalence
Overall, 0.37% of the extrapolated Swiss population were
defined as having IBD between 2010 and 2014. The per-
centages of Swiss IBD patients totaled up to 0.32% in
2010, 0.38% in 2012, and 0.41% in 2014. Prevalence esti-
mates of IBD extrapolated to the general Swiss popula-
tion by age, sex, and canton of residence with the
corresponding confidence intervals (CI) for the three
given years are shown in Table 1.The differences in the characteristics between the IBD
and the non-IBD sample are shown in Table 2. Prevalence
rates were significantly higher in the German (0.40%)
and the Italian speaking part (0.42%) of Switzerland,
compared with the French speaking part (0.31%). We
found higher prevalence estimates of IBD in urban
compared with rural areas. Concerning the health in-
surance plan, IBD patients were less frequently enrolled
in a managed care model and more frequently had sup-
plementary private hospital insurance coverage.
Using logistic regression modeling, we found that
women were more likely to have an IBD diagnosis: the
overall adjusted sex-difference in the proportion of IBD
patients was OR 1.16 (CI: 1.12-1.20, p < 0.001), when
taking age group and canton of residence into account.
The prevalence estimates increased strongly with older
age, in men (OR = 25.82, CI: 20.29-33.51, p < 0.001), and
women (OR = 23.11, CI: 18.37-29.62, p < 0.001), com-
pared with their youngest counterparts. When compar-
ing three time points within 5 years, we found an overall
annual increase in the prevalence of 6% (OR = 1.06, CI:
1.05-1.07, p < 0.001) between 2010 and 2014, allowing
for the varying distribution of age, sex and the canton of
residence of the individuals.
Based on the study population, the most frequently
prescribed medications in patients with IBD were 5-
ASA. However, the proportion of patients with at least
one claim for mesalazine or sulfasalazine decreased,
whereas the prescription of immunosuppressants and bi-
ologics increased in the given time span (Table 3).
In a sub-analysis we compared the prevalence rate
estimated by means of the IBD definition described
above (using ATC codes) with a main listing of ICD-10
diagnosis of UC or CD (K50, K51) in hospitalized pa-
tients in 2014. We found a sensitivity of 60.5% and a
specificity of 99.1%.
Table 2 Characteristics of the study population in 2014
n (%) Total IBD Non-IBD pa
n = 1,125,050 n = 4812 n = 1,120,238
Female sex 581,598 (51.7) 2695 (56.0) 578,903 (51.7) <0.001
Age
Total (mean, SD) 44.0 (23.5) 54.8 (18.0) 43.9 (23.5) <0.001
Men (mean, SD) 42.3 (22.8) 54.2 (17.5) 42.2 (22.8)
Women (mean, SD) 45.5 (24.0) 55.4 (18.5) 45.5 (24.0)
Language areab
German 840,900 (74.7) 3778 (78.5) 837,122 (74.7) <0.001
French 209,719 (18.6) 687 (14.3) 209,032 (18.7)
Italian 74,413 (6.6) 347 (7.2) 74,066 (6.6)
Type of residence (urban area) 874,640 (77.7) 3799 (78.9) 870,841 (77.7) 0.04
Chronic conditions (median, IQR) 0.0 (2.0) 3.0 (3.0) 0.0 (2.0) <0.001
Home care nursing dependency 30,669 (2.7) 285 (5.9) 30,384 (2.7) <0.001
Health insurance plan
Managed care 649,992 (57.8) 2340 (48.6) 647,652 (57.8) <0.001
Higher deductible 308,642 (27.4) 522 (10.8) 308,120 (27.5) <0.001
Accident coverage 677,107 (60.2) 2871 (60.0) 674,236 (60.2) ns
Supplementary hospital insurance 208,661 (18.5) 1020 (21.2) 207,641 (18.5) <0.001
Purchasing power
1 (high) 224,750 (20.0) 956 (19.9) 223,794 (20.0) ns
2 223,464 (19.9) 942 (19.6) 222,522 (19.9)
3 224,857 (20.0) 961 (20.0) 223,896 (20.0)
4 222,979 (19.8) 984 (20.4) 221,995 (19.8)
5 (low) 229,000 (20.4) 969 (20.1) 228,031 (20.4)
ap-values, assigning the differences between the IBD and non-IBD populations, were calculated using fisher’s exact test for dichotomous variables, using Wilcoxon
rank sum test for continuous, and using chi-squared test for categorical variables; ns = not significant
bRhaeto-Romanic area is assigned to the German area
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Overall, 1.3% of IBD patients died between 2010 and
2014. The proportion of decedents in the non-IBD co-
hort amounted to 0.8%. However, this difference is not
statistically significant when adjusting for age and sex
(OR = 1.09; CI: 0.95-1.24, p = 0.234). The median (IQR)
age was 81.0 (13.8) years in decedents with and 83.0
(16.0) years in decedents without IBD (p = 0.001).Table 3 Percentage of IBD patients with at least one of the
listed medical claims (n = 13,451)
% Total 2010 2012 2014
5-ASAa 87.4 96.8 84.8 82.2
Immunosuppressantsb 23.2 18.7 24.4 25.9
Biologicsc 9.7 5.3 10.2 12.8
Steroidsd 35.0 32.8 36.5 35.3
amesalazine, sulfasalazine
bmethotrexate, azathioprine, mercaptopurine
cinfliximab, adalimumab, golimumab, certolizumab pegol
dprednisone, prednisolone, methylprednisolone, budesonideThe mortality estimates of male IBD patients ranged
from 1.2% (0.8-1.6%) in 2010 and 1.2% (0.7-1.5%) in
2012 to 1.8% (1.3-2.3%) in 2014, when extrapolated to
the Swiss general population. The corresponding esti-
mates in women were 1.1% (0.8-1.5%), 1.4% (1.0-1.8%),
and 1.0% (0.7-1.4%), respectively. There was no signifi-
cant change in all-cause mortality rate over the observed
time span, when controlling for age group, sex and the
canton of residence: OR = 1.02 (CI: 0.94-1.11, p = 0.662).
However, as the number of decedent IBD patients was
rather small, these data have to be interpreted with
caution.
Health care costs
Median (CI) total health care costs per IBD patient
extrapolated to the Swiss population were CHF 5390
(5170-5610), CHF 6090 (5800-6370), and CHF 6810
(6520-7100) in 2010, 2012, and 2014, respectively, com-
pared with CHF 750 (740-750), CHF 780 (780-790), and
CHF 870 (860-870), in non-IBD patients (Table 4).
Table 4 The extrapolated health care costs (in Swiss Francs) in IBD versus non-IBD patients between 2010 and 2014
Mean (CI, median) IBD non-IBD pa
2010
Total 9590 (9210-9970, 5390) 3160 (3140-3170, 750) <0.001
Inpatient 2040 (1830-2240, 0) 890 (880-890, 0) <0.001
Outpatient 3920 (3790-4040, 2810) 1510 (1500-1510, 490) <0.001
Medication 3630 (3430-3840, 1700) 760 (760-770, 100) <0.001
2012
Total 11,680 (11,230-12,140, 6090) 3380 (3360-3390, 780) <0.001
Inpatient 2080 (1860-2300, 0) 950 (940-960, 0) <0.001
Outpatient 4470 (4300-4640, 3110) 1630 (1630-1640, 520) <0.001
Medication 5130 (4840-5430, 1900) 790 (790-800, 110) <0.001
2014
Total 12,790 (12,270-13,300, 6810) 3540 (3520-3560, 870) <0.001
Inpatient 2150 (1870-2430, 0) 910 (900-920, 0) <0.001
Outpatient 5280 (5070-5490, 3510) 1830 (1830-1840, 610) <0.001
Medication 5360 (5100-5620, 1900) 800 (790-800, 110) <0.001
ap-values were calculated using multivariate linear regression (adjusted for age group, sex, and canton of residence)
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at all in the given year. Overall, total direct costs in-
curred by IBD patients were substantially higher com-
pared to the non-IBD sample (OR = 4.97, CI: 4.85-5.10,
p < 0.001), having adjusted for age, sex, canton of resi-
dence, and year of observation. Additional file 2: Table
S2 presents the median total health care costs of the
IBD and the non-IBD sample for the years 2010-2014,
extrapolated to the Swiss population, by sex and age
group. In total, female IBD patients incurred higher
costs compared to male patients throughout the three
observed time points (OR = 1.62, CI: 1.61-1.62, p <
0.001), having adjusted for age, canton of residence, and
year of observation. The overall costs in patients aged
17 years and younger shown in Additional file 2: Table
S2 should be interpreted with caution due to low sample
sizes.
The extrapolated mean total health care costs incurred
by IBD patients were about four times higher in 2014
compared with those of the non-IBD Swiss population
(Table 4). Extrapolated medication costs were even more
than 6 times higher in IBD patients in this same year. In
IBD patients, the proportion of medication costs as well
as of the other outpatient services amounted to 42%
each, whereas only 16% of the costs were due to hospital
admissions in 2014. Four years earlier, the proportion of
inpatient costs made up 21% of the total costs. A
more detailed description of the health care costs in
the IBD versus the non-IBD sample are provided in
Additional file 3: Table S3.
Based on our analysis of three time points within 5
years, total health care costs showed an annualincrease of 2.4% (OR = 1.024, CI: 1.023-1.025, p < 0.001) in
the non-IBD sample, and of 6.0% (p < 0.001) in IBD pa-
tients, when age, sex and canton of residence were taken
into account. In IBD patients, the increase was solely due
to increased costs of outpatient services (OR = 1.06, CI:
1.05-1.08, p < 0.001), and medication costs (OR = 1.05, CI:
1.04-1.06, p < 0.001), while there was no significant change
in inpatient costs between 2010 and 2014 (OR = 1.00, CI:
0.98-1.02, p = 0.975). Similarly, in non-IBD patients, out-
patient costs (OR = 1.036, CI: 1.035-1.037, p < 0.001),
and to a lesser extent, medication costs (OR = 1.002,
CI: 1.001-1.002, p < 0.001) increased, while inpatient
costs remained stable (OR = 1.00, CI: 1.00-1.01, p = 0.528;
Figs. 1, 2 and 3).
Further analyses were conducted to examine the asso-
ciation between the preselected socio-demographic, clin-
ical and regional predictors and the total health care
costs in IBD patients (Table 5). Total health care costs
were lower in patients aged 60 years and older compared
to patients aged 1-17 years, in both men and women.
Less surprisingly, the number of chronic conditions and
nursing dependency led to increased total costs. IBD
patients in managed care model had 13% lower total
costs compared with those in traditional model. In the
Italian speaking part (as compared with the German
speaking part), costs of IBD patients were associated
with a decrease of 14%.
The type of residence was not included in the final
model as urbanity was no longer significant once lan-
guage area was taken into account. No association with
total costs was found for purchasing power and supple-
mentary private hospital insurance.
Fig. 1 Bar-plot of the mean annual inpatient costs (in Swiss Francs) of IBD and non-IBD patients, extrapolated to the general Swiss population for
the years 2010, 2012, and 2014, respectively
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Overall, the number of individuals demanding health care
was significantly higher in the IBD compared to the non-
IBD-sample. In 2010, 97.6% of the IBD patients and 74.0%
of the non-IBD sample had at least one physician visit. The
corresponding proportions were 98.0% and 76.4% in 2012,
and 98.3% and 77.7% in 2014, respectively. The median
(CI) number of visits per IBD patient in the extrapolated
Swiss population were 13 (12-14), 15 (14-16), and 15 (15-
16) in 2010, 2012, and 2014, respectively, compared with a
median number of 3 (3-3), 4 (4-4), and 4 (4-4) in the non-
IBD sample in the corresponding years. IBD patients had aFig. 2 Bar-plot of the mean annual outpatient costs (in Swiss Francs) of IBD
for the years 2010, 2012, and 2014, respectivelysubstantially higher number of annual physician visits (OR
= 2.75, CI: 2.70-2.80, p < 0.001), compared to those without
IBD, after adjustments for age, sex, canton of residence,
and year of observation. Female IBD patients have con-
tacted physicians more frequently (adjusted OR = 1.30, CI:
1.26-1.33, p < 0.001) than male IBD patients.
The total number of visits increased by 3.7% (OR = 1.04,
CI: 1.03-1.05, p < 0.001) in IBD-patients over the observed
time period, when age, sex and canton of residence were
taken into account. Differences between IBD and non-
IBD patients regarding the number of visits to primary
care physicians, to specialists and the number of hospitaland non-IBD patients, extrapolated to the general Swiss population
Fig. 3 Bar-plot of the mean annual medication costs (in Swiss Francs) of IBD and non-IBD patients, extrapolated to the general Swiss population
for the years 2010, 2012, and 2014, respectively
Table 5 Multiple linear regression model on the total health
care costs in IBD patients in 2014 (n = 4812)
β (95% CI) p
Age group by males
1-17 (male) 1.00
18-40 (male) 0.59 (0.39-0.91) 0.016
41-60 (male) 0.47 (0.30-0.71) <0.001
60+ (male) 0.44 (0.29-0.67) <0.001
Age group by females
1-17 (female) 1.00
18-40 (female) 1.04 (0.72-1.49) 0.840
41-60 (female) 0.79 (0.55-1.13) 0.195
60+ (female) 0.59 (0.41-0.85) 0.004
Number of chronic conditions 1.31 (1.29-1.33) <0.001
Nursing dependency 1.89 (1.69-2.12) <0.001
Language area
German 1.00
French 1.03 (0.96-1.11) 0.375
Italian 0.86 (0.78-0.95) 0.003
Health insurance plan
Higher deductible class 0.65 (0.60-0.71) <0.001
Accident coverage 1.10 (1.03-1.18) 0.004
Managed care 0.87 (0.83-0.92) <0.001
Supplementary insurance 1.06 (0.99-1.14) 0.061
R2 0.337
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S4. The greatest difference regarding the number of visits
referred to specialist visits.
The proportion of IBD patients with at least one
hospitalization in a given year ranged between 23.1%
and 24.2% during the observed time span. In contrast,
only 10.8% to 10.9% of patients without IBD were hospi-
talized at least once in the corresponding years. The
median (IQR) and mean (SD) length of hospital stay
amounted to 7 (14) and 15.2 (23.4), respectively 5 (9)
and 14.0 (29.5) days in those hospitalized patients.
Sub-analyses of IBD patients in 2014
Finally, we analyzed health care costs and utilization in
IBD patients, thereby comparing individuals with and
without any prescription for biologics (infliximab, adali-
mumab, golimumab, certolizumab pegol). Of the 4812
IBD patients in 2014, 620 (12.9%) were treated with
biologics. Characteristics of the two groups are shown in
Table 6. Biologics were more frequently prescribed in
younger patients, and in patients living in the French
speaking part of Switzerland, as well as in those living in
urban areas.
The total costs incurred by patients treated with bio-
logics were almost three times higher compared with pa-
tients without biologics (Table 7). In the multivariate
regression model controlling for socio-demographic
(age, sex, and type of insurance coverage), clinical (number
of chronic conditions, nursing dependency) and regional
(language area, type of residence) factors, the costs were
even four times higher (OR = 3.98, CI: 3.72-4.27, p < 0.001).
More than 70% of the total costs were due to medication
costs in patients with biologics, compared with 28% in
Table 6 Characteristics of IBD patients treated with or without biologics in 2014 (n = 4812)
n (%) IBD (total) No Biologics Biologics pa
n = 4812 n = 4192 n = 620
Female sex 2695 (56.0) 2461 (56.1) 234 (55.1) ns
Age
Total (mean, SD) 54.8 (18.0) 55.9 (17.9) 43.6 (15.7) <0.001
Men (mean, SD) 54.2 (17.5) 55.4 (17.2) 41.8 (15.4)
Women (mean, SD) 55.4 (18.5) 56.4 (18.4) 45.1 (15.8)
Language areab
German 3778 (78.5) 3473 (79.2) 305 (71.8) <0.001
French 687 (14.3) 582 (13.3) 105 (24.7)
Italian 347 (7.2) 332 (7.6) 15 (3.5)
Type of residence (urban area) 3799 (78.9) 3446 (78.6) 353 (83.1) 0.03
Health insurance plan
Managed care 2340 (48.6) 2154 (49.1) 186 (43.8) 0.04
Higher deductible 522 (10.8) 509 (11.6) 13 (3.1) <0.001
Accident coverage 2871 (59.7) 2660 (60.6) 211 (49.7) <0.001
Supplementary hospital insurance 1020 (21.2) 948 (21.6) 72 (16.9) 0.03
Home care nursing dependency 285 (5.9) 263 (6.0) 22 (5.2) <0.001
ap-values, assigning the differences between IBD patients treated with and without biologics, were calculated using fisher’s exact test for dichotomous variables,
using Wilcoxon rank sum test for continuous, and using chi-squared test for categorical variables; ns = not significant
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fer significantly between the two groups except for the in-
patient costs.
Only 1.7% of the IBD patients without biologics and
none of the patients with biologics did not have any con-
sultation in 2014. The median (IQR) total number of visits
amounted to 22 (19) in IBD-patients with and to 15 (18)
in patients without biologics in those with at least one
consultation (p < 0.001). The median (IQR) number of
visits to primary care physicians and to specialists was 4
(8) and 9 (12) in IBD-patients with, and 5 (9) and 5 (8) in
IBD patients without biologics, respectively.
The proportion of IBD patients with at least one hos-
pital admission in 2014 was 25.6% and 22.1% in patients
with and without biologics, respectively (p = 0.06). The
median (IQR) and mean (SD) length of hospital stayTable 7 Health care costs (in Swiss Francs) of IBD patients treated w
Mean (SD, median) No Biologics
Total 10,437 (15,146, 5833)
Inpatient 2308 (8340, 0)
Outpatient 5163 (6912, 3368)
Primary care physicians 635 (777, 417)
Specialists 1516 (1854, 941)
Others (e.g. paramedical) 3012 (6044, 1401)
Medications 2966 (5464, 1644)
ap-values were calculated using Wilcoxon rank sum testamounted to 7 (11) and 12 (13) in those treated with bi-
ologics, and 8 (15) and 17 (27) days to in those treated
without biologics. Thus, no significant differences
regarding the inpatient setting were found between the
two groups of IBD patients.
Discussion
Prevalence and mortality rates of IBD
Based on our analysis of three time points within 5 years,
we found an overall extrapolated prevalence rate of IBD
of 0.37%, whereby the rate increased from 0.32% in
2010, to 0.38% in 2012, and to 0.41% in 2014. This is
comparable to estimates in Sweden (0.35%), Finland
(0.44%), the US (0.44%) and Canada (0.5%) [4–6, 34].
According to a recently published review by Burisch and
colleagues, [15] 0.3% of the population had IBD inith or without biologics in 2014 (n = 4812)
Biologics pa
28,265 (12,970, 25,779) <0.001
1887 (4790, 0) 0.3
6303 (4830, 4956) <0.001
551 (769, 285) <0.001
2026 (2191, 1509) <0.001
3726 (3630, 2692) <0.001
20,075 (9486, 19,316) <0.001
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lower than that of a large German insurance-based
cohort with 493/100,000 actively treated IBD patients in
2010 (age- and sex-standardized to the German popula-
tion) [35]. According to a previous Swiss study, [26] the
estimated prevalence rate for Switzerland was 206/
100,000. The incidence of both, CD and UC, were
shown to have increased in Switzerland since then, [25]
which was also observed in other countries [9]. In a
large US cohort study, the prevalence rates in 2009 were
241/100,000 for CD and 263/100,000 for UC adult pa-
tients (20 years and older), respectively. These rates cor-
respond to an increase compared with the years 2003/
2004, where 201/100,000 were estimated to have CD
and 238/100,000 were estimated to have UC [5, 7]. In
their claims data based study, patients with at least one
IBD-specific medication, combined with at least one
claim for CD or UC, were also included in their case
definition [7].
According to our analysis, IBD was more prevalent in
women compared to men (403/100,000 vs. 331/100,000),
and was lower in persons aged 17 years and younger
(24/100,000) as compared with all other age groups.
Similarly, a higher rate of female compared to male IBD
patients was reported for the Swiss IBD Cohort, [36, 37]
as well as for other countries in Europe [17, 35]. In US
children, prevalence rates were estimated to be 43/
100,000 for CD and 28/100,000 for UC, respectively,
which is slightly higher than in our findings [38]. How-
ever, our results need to be interpreted with caution, as
the sensitivity of our defined IBD identification algo-
rithm is relatively small, whereas the estimated specifi-
city was found to be high. In other words, we possibly
underestimate the number of patients with IBD. Reasons
for the comparably low sensitivity might, firstly, be due
to the fact that we were unable to detect patients with
mild disease who weren’t treated with one of the defined
medications [37]. Secondly, there might be incident
cases without a history of IBD-related medications.
Thirdly, when medications are administered during
hospitalization, coding for this treatment is missing by
means of our data. Lastly, as the disease is characterized
by relapsing intestinal inflammation, the medical treat-
ment varies. However, in absence of clinical data like
ICD codes, the use of highly reliable medical claims to
estimate the burden of a chronic disease is common. A
previous validation study on IBD based on an adminis-
trative database has found a sensitivity of 88.9% and
89.2% and a specificity of 91.2% and 89.8% for CD when
comparing self-reports with chart-reviews, and a sensi-
tivity of 87.7% and 74.4% and a specificity of 91.3% and
93.7% for UC, respectively [39].
Looking solely at medical claims, the percentage of
IBD patients with a drug prescription amounted to 19%for immunosuppressants and 5% for biologics in our
study in 2010. The corresponding figures were 19% and
3% in a Swedish study [34]. In contrast, their prescrip-
tion rates for aminosalicylates were considerably lower
[34]. In a Dutch study, 30.1% of the IBD patients
received immunosuppressants, 15.1% received biologics,
and 39.7% were on 5-ASA in 2011 (as compared with
84.8% of patients with 5-ASA in 2012 in our study) [17].
We found no increased mortality ratio in patients with
IBD compared to the non-IBD cohort. This is in line
with previous studies in the Netherlands, Finland or
North America [40–42]. Further previous studies asses-
sing mortality rates in IBD patients found a higher mor-
tality ratio in CD, but not UC patients, for example in
the US, Denmark, or in overall Europe [15, 43, 44]. In
contrast, slightly higher rates were found for overall IBD
patients, [45–47] that were commonly more pronounced
in younger patients [43, 46]. Mortality rates were shown
to decrease over the last decades, especially in hospital-
ized patients [48].Health care costs and health care utilization
Based on our findings, the extrapolated median (mean)
total health care costs per IBD patient in Switzerland were
CHF 5390 (9590) in 2010, CHF 6090 (11,680) in 2012, and
costs increased to CHF 6810 (12,790) in 2014. According
to a review by Yu et al. [49] published in 2008, estimated
annual direct medical costs per CD patient were approxi-
mately 18,000 to 19,000 US$ in the US, and approximately
4000 to 10,000 US$ (converted) in other Western countries.
Similarly, lower costs for the treatment of CD and UC in
Europe compared to the US have been shown in the review
by Odes [50]. From 1999 to 2005, annual medical costs per
patient were estimated to be 18,963 in CD patients versus
5300 US$ in controls, and 15,020 in UC patients versus
4982 US$ in controls in the US [51]. The calculated in-
crease in total costs in our study is in line with international
findings. Based on health claims data, the average annual
medical costs per patient with CD and UC amounted to
6561 US$ and 1488 US$, respectively, in the US in 1990
[52]. Thirteen to fourteen years later, the direct medical
costs of CD and UC per patient per year were estimated
to be 10,952 US$ (with CD associated treatment costs
of US$ 8265) and 7948 US$ (with UC associated
treatment costs of US$ 5066) from a social insurance
payer perspective, respectively [18].
Based on our study findings, women incurred higher
total health care costs than men. And in the multivariate
regression model on total costs in IBD patients, costs
were highest in the youngest age group. However, the
confidence interval in the youngest patients are wide,
suggesting great variance and heterogeneity in the man-
agement of the youngest patients.
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differences were found concerning total health care costs
in a large US study [18]. In that same study, younger
patients (aged <20 years) were shown to incur higher
mean annual health care costs compared to their older
counterparts, especially in CD patients [18, 53]. The
higher costs in the youngest age group were explained 1)
by a higher number of incident cases in this age group,
2) by a more severe course of disease when IBD is diag-
nosed at young age, and moreover 3) by a possibly more
progressive treatment pattern of pediatric gastroenterol-
ogists [18].
There has been a shift from inpatient to outpatient
costs in recent years, due to the introduction of new
medical therapies like biologics, mainly in patients with
CD [16, 18, 50]. This is comparable to our results, where
outpatient costs made up 79% in 2010 and 84% in 2014.
However, the increase in outpatient costs might also be
a consequence of the introduction of the Swiss DRG in
2012, which might have led to a shift of treatments and
dispensing of medications from the inpatient to the out-
patient setting. In earlier studies conducted in the US,
[49, 52] and in European countries, [19, 49] more than
half of the total costs were attributable to inpatient costs.
Medical and surgical hospitalization made up a little
more than 30% in a US study conducted between 2003
and 2004 [18]. In a recent Dutch study [17] that looked
at the societal perspective of the costs of IBD, medica-
tion costs accounted for 71% of the total costs in CD
and for 59% in UC patients. Inpatient costs made up
as little as approximately 20% of the total costs in
2011 [17].
In 2014, 98.3% of IBD patients in our sample had at
least one physician visit. The extrapolated median (IQR)
number of visits per IBD patient was 15 (15-16) in 2014,
compared to 4 (4-4) in the non-IBD sample, whereby
the greatest differences referred to specialist visits. The
proportion of IBD patients with at least one hospital
admission in 2014 was nearly 24%. The median (mean)
length of hospital stay amounted to 7 (16) days in those
patients.
In a previous Swiss study, [37] the mean (± SD) num-
ber of outpatient visits was 2.1 (± 3.6) and 2.3 (± 3.2) in
UC and CD patients during the 3-months follow-up,
respectively, whereby patients more frequently consulted
a specialist rather than a primary care physician in their
analyses as well. However, they only investigated IBD-
related resource consumption, whereas we didn’t con-
sider the reason for hospitalization or consultation. Al-
most 14% of the IBD patients were hospitalized for at
least 1 day in their 12-months follow-up [37]. Their cal-
culated mean (± SD) number of days in hospital was 1.5
(± 6.1) and 2.0 (± 8.8) in UC and CD patients, respect-
ively. Yet, they didn’t exclude patients without anyconsultation or hospitalization in their study. Similarly,
about 14% of the IBD patients were hospitalized in the
UK [54]. In a Swedish study, 24% of the IBD patients
had undergone at least one major IBD-related surgery
during the study period [34]. According to a recent
review, the hospitalization rates varied considerably
between European countries [15]. The proportion of
IBD patients with surgery ranged between 0.5% in an
Hungarian and 35% in a Danish cohort during 1 year of
observation. To conclude, the diversity in the definition
or classification of visits does not allow always for direct
comparison of the results found in our study with previ-
ous study findings.Comparison of IBD patients with and without the use of
biologics
In 2014, 13% of all IBD patients in the Helsana cohort
received biologics. They incurred four times higher total
costs compared with patients without such a prescrip-
tion. About 70% of the costs were attributable to medi-
cation costs. But the higher medication costs were not
compensated by lower inpatient costs. However, these
results need to be interpreted with caution as we could
not take the year of diagnosis or the disease severity into
account. It is known that patients treated with biologics
are mostly affected by a more severe disease course. Fur-
thermore, inpatient costs were not limited to an IBD-
related hospitalization.
Thus, similar results were found by Kappelman et al.
[18] in 2003 and 2004. According to their study, bio-
logics (namely infliximab) were the most expensive med-
ications in CD patients, whereas aminosalicylates were
the most costly drugs in UC patients. A higher con-
sumption of health care resources in patients treated
with biologics has also been found in further studies [37,
55]. The higher resource consumption mainly occurred
in the first 1-3 years after initiation of the treatment in
those analyses, which might be another reason for the
higher costs in young patients reported in our study.
In contrast, a Danish cohort study has demonstrated
that the increased use of thiopurines and biologics in
IBD over time was associated with a persistent signifi-
cant decrease in surgery rates, along with a significant
decrease in the use of 5-ASA and corticosteroids [56].
The study, however, did not have the power to demon-
strate a surgery-sparing effect of these newer medica-
tions [56]. The Swiss study by Safroneeva et al. [57]
demonstrated that early treatment of CD patients with
immunosuppressants and biologics was associated with
reduced risk of developing bowel strictures, and early
immunosuppressants reduced the risk of intestinal and
perianal surgery. Therefore, further research with longer
follow-up periods is needed.
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The strength of the present study is the large number of
patients included that enabled us to give a representative
overview of the IBD situation in Switzerland. To the best
of our knowledge, this is the first study to explore preva-
lence, mortality as well as health care costs and utilization
for IBD patients treated in all settings in Switzerland.
Moreover, the data weren’t collected by means of self-
report and therefore results were not distorted due to
recall bias.
One major limitation of this study is the fact, that we
were lacking diagnosis information in the ambulatory
setting. Since medication therapy is the main pillar in
the treatment of IBD patients [20, 22, 58] the identifica-
tion of patients via ATC codes seems natural. The com-
bination of at least one claim for UC and CD and at
least one pharmacy claim for 5-ASA, Immunosuppres-
sants or biologics has been used in previous studies on
the prevalence and health care costs of patients with CD
and UC [5, 18]. Due to the selected ATC codes for the
definition of IBD, patients with mild disease severity are
likely to be underrepresented. This in turn may lead to
an overestimation of the health care costs of IBD
patients when compared with a non-IBD population as
we more likely missed those cases incurring lower costs.
Because of the known diagnostic delay distinctive of
IBD, as well as the relapsing and remitting nature of
IBD, the number of IBD patients may be even higher
[59, 60]. Furthermore, this study is based on outpatient
prescription drug dispending and does not consider
medications applied during hospitalizations. Moreover,
patients who consulted a pediatric gastroenterologist
who is registered as a pediatrician rather than a gastro-
enterologist might be misclassified as not having IBD.
This may lead to an underestimation of the prevalence
of IBD, especially in younger patients.
A second major limitation is the fact that time trends
are based on the analysis of three time points over a 5-
year-period. One should therefore be careful drawing
conclusions on time trends.
It is conceivable that further factors might influence
the study findings, like the time of diagnosis or the treat-
ment delay, which cannot be identified by means of the
Helsana data [61]. In addition, we were not able to dis-
criminate between health care costs and utilization that
were solely attributable to IBD.
Conclusions
Based on our analysis of three time points within 5
years, the prevalence rates of IBD seem to have in-
creased in Switzerland. There was a shift from inpatient
to outpatient costs in IBD patients, although no signifi-
cant reduction in inpatient costs was observed between
2010 and 2014. Similarly, we found substantially highermedication costs in IBD patients treated with biologics
that were not compensated by lower inpatient costs,
compared with IBD patients without a prescription for
biologics. However, more research with longer follow-up
duration is needed to confirm these results.
Owing to new pharmacotherapies and changes in the
management of the disease, there is a lack of research
on the health care costs and utilization based on those
pharmacotherapies used in clinical practice in patients
with IBD. Further research is needed to demonstrate the
burden of disease and the management of patients, sep-
arately for UC and CD, and to find the best possible
pharmacologic intervention for each patient.Additional files
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